Reliable Detection and Quantification of Protein Impurities

Article

Automatic and reliable detection and quantification of low concentrated protein impurities down to 0.05% and below with the Agilent 2100 Bioanalyzer!

The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit allows you to reliably detect and quantify low concentrated impurities next to massive main components — down to 0.05% and below. This meets the ICH guideline Q3B(R2): Impurities in New Drug Products! Reporting threshold 0.05% for a maximum daily dose >1g.

The Agilent 2100 Bioanalyzer provides:

  • sensitivity and linear dynamic range — silver stain sensitivity down to 1 pg/µL of labeled protein on chip and 4 orders of magnitude in linear dynamic range
  • fast results — complete automated analysis of 10 samples in 30 minutes
  • reproducibility — qualitative, user-independent and digital data
  • ease of use - standardized assay, pre-packaged reagent kits
  • 21 CFR Part 11 compliance — validated reagents and software plus Agilent compliance services to meet all GMP/GLP needs

The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is suited excellent to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines — in the Bioanalyzer-like, fast and reproducible way.

Learn more!
Receive a free Protein QC application CD!

Contact:
Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group
5301 Stevens Creek Boulevard
Santa Clara, CA 95051-7201
USA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content